ZA200602858B - HIV vaccines based on Env of multiple clades of HIF - Google Patents
HIV vaccines based on Env of multiple clades of HIFInfo
- Publication number
- ZA200602858B ZA200602858B ZA200602858A ZA200602858A ZA200602858B ZA 200602858 B ZA200602858 B ZA 200602858B ZA 200602858 A ZA200602858 A ZA 200602858A ZA 200602858 A ZA200602858 A ZA 200602858A ZA 200602858 B ZA200602858 B ZA 200602858B
- Authority
- ZA
- South Africa
- Prior art keywords
- hif
- env
- vaccines based
- hiv vaccines
- multiple clades
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50350903P | 2003-09-15 | 2003-09-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200602858B true ZA200602858B (en) | 2008-05-28 |
Family
ID=34434858
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200602858A ZA200602858B (en) | 2003-09-15 | 2006-04-07 | HIV vaccines based on Env of multiple clades of HIF |
Country Status (8)
Country | Link |
---|---|
US (4) | US20060275897A1 (xx) |
EP (1) | EP1675613B1 (xx) |
CN (1) | CN1913919B (xx) |
AU (1) | AU2004279362B2 (xx) |
CA (1) | CA2539068C (xx) |
ES (1) | ES2388527T3 (xx) |
WO (1) | WO2005034992A2 (xx) |
ZA (1) | ZA200602858B (xx) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2563396A1 (en) * | 2004-04-12 | 2005-11-24 | The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services | Method of using adenoviral vectors to induce an immune response |
TW200613554A (en) * | 2004-06-17 | 2006-05-01 | Wyeth Corp | Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV |
AU2005274948B2 (en) * | 2004-07-16 | 2011-09-22 | Genvec, Inc. | Vaccines against aids comprising CMV/R-nucleic acid constructs |
ES2281252B1 (es) * | 2005-07-27 | 2009-02-16 | Consejo Superior De Investigaciones Cientificas | Vectores recombinantes basados en el virus modificado de ankara (mva) como vacunas preventivas y terapeuticas contra el sida. |
CN101969996A (zh) | 2005-08-23 | 2011-02-09 | 加利福尼亚大学董事会 | 多价疫苗 |
US7951377B2 (en) * | 2005-08-23 | 2011-05-31 | Los Alamos National Security, Llc | Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens |
CA2626257A1 (en) * | 2005-10-17 | 2007-04-26 | Novartis Ag | Multiclade hiv vaccines |
US20090155853A1 (en) * | 2005-11-18 | 2009-06-18 | Gary Nabel | Non-viral gene delivery complex |
WO2007100584A2 (en) * | 2006-02-16 | 2007-09-07 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antiviral agents and vaccines against influenza |
WO2007107810A1 (en) * | 2006-03-20 | 2007-09-27 | Council Of Scientific And Industrial Research | A method for detecting the presence of water born pathogens and indicator microorganism |
WO2008005929A2 (en) * | 2006-06-30 | 2008-01-10 | New York University | Recombinant hiv-1 gp120 immunogen with three different v3 loops from viruses of different clades |
EP2152889B1 (en) | 2007-05-29 | 2017-03-15 | Nature Technology Corporation | Vectors and methods for genetic immunization |
WO2010042817A1 (en) * | 2008-10-10 | 2010-04-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of hiv mosaic envelope proteins to optimize t-cell responses against hiv envelope |
CN102317308A (zh) | 2008-11-26 | 2012-01-11 | 美国国有健康与人类服务部 | 类病毒组合物颗粒及其使用方法 |
EP2405945A4 (en) * | 2009-03-13 | 2012-09-12 | Lentigen Corp | NON-INTEGRAL RETROVIRAL VECTOR VACCINES |
CN101569745A (zh) * | 2009-05-25 | 2009-11-04 | 苏州工业园区唯可达生物科技有限公司 | 抗多种艾滋病毒的组合疫苗及其组合方法 |
US9175070B2 (en) | 2009-09-25 | 2015-11-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to HIV-1 and their use |
WO2011047316A1 (en) | 2009-10-16 | 2011-04-21 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Nucleic acid sequences encoding expandable hiv mosaic proteins |
WO2011057254A2 (en) | 2009-11-09 | 2011-05-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Simian adenoviral vector-based vaccines |
US9597379B1 (en) | 2010-02-09 | 2017-03-21 | David Gordon Bermudes | Protease inhibitor combination with therapeutic proteins including antibodies |
US8771669B1 (en) | 2010-02-09 | 2014-07-08 | David Gordon Bermudes | Immunization and/or treatment of parasites and infectious agents by live bacteria |
US8524220B1 (en) | 2010-02-09 | 2013-09-03 | David Gordon Bermudes | Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria |
EP2579892A2 (en) | 2010-06-09 | 2013-04-17 | Vaccine Technologies, Incorporated | Therapeutic immunization in hiv infected subjects receiving stable antiretroviral treatment |
WO2012021730A2 (en) * | 2010-08-11 | 2012-02-16 | Genvec, Inc. | Respiratory syncytial virus (rsv) vaccine |
AU2012308149A1 (en) | 2011-09-12 | 2014-03-27 | Sheena Mary Geraldine MCCORMACK | Methods and compositions for raising an immune response to HIV |
CN108676091B (zh) | 2011-12-08 | 2022-04-01 | 美国政府(由卫生和人类服务部的部长所代表) | Hiv-1的中和抗体及其用途 |
US9738688B2 (en) * | 2012-11-05 | 2017-08-22 | International Aids Vaccine Initiative | HIV-1 envelope glycoprotein |
CA3156357A1 (en) * | 2014-01-06 | 2015-07-09 | The Trustees Of The University Of Pennsylvania | Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy |
US9737592B1 (en) | 2014-02-14 | 2017-08-22 | David Gordon Bermudes | Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
WO2019018475A1 (en) * | 2017-07-18 | 2019-01-24 | The Board Of Trustees Of The University Of Illinois | HIV-1 ENV MODIFIED VARIANTS FOR THE PRESENTATION OF QUATERNARY EPITOPES |
MA55321A (fr) * | 2019-03-15 | 2022-01-19 | Modernatx Inc | Vaccins à base d'arn contre le vih |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1234567A (en) * | 1915-09-14 | 1917-07-24 | Edward J Quigley | Soft collar. |
WO1996039178A1 (en) | 1995-06-05 | 1996-12-12 | The Wistar Institute Of Anatomy And Biology | A replication-defective adenovirus human type 5 recombinant as a vaccine carrier |
US5741492A (en) * | 1996-01-23 | 1998-04-21 | St. Jude Children's Research Hospital | Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses |
US6900010B2 (en) * | 1999-01-25 | 2005-05-31 | Musc Foundation For Research Development | Compositions and methods for detecting human immunodeficiency virus |
DK1240186T3 (da) * | 1999-12-23 | 2010-05-31 | Medical Res Council | Forbedringer i eller relateret til immunrespons mod HIV |
US8623379B2 (en) * | 2000-03-02 | 2014-01-07 | Emory University | Compositions and methods for generating an immune response |
JP5052732B2 (ja) * | 2000-08-14 | 2012-10-17 | アメリカ合衆国 | 遺伝的免疫化のための免疫原性を強化するHIVEnv、Gag、およびPolの改変 |
US6733993B2 (en) * | 2000-09-15 | 2004-05-11 | Merck & Co., Inc. | Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications |
AU2002252199B2 (en) * | 2001-03-08 | 2008-01-03 | Emory University | MVA expressing modified HIV envelope, GAG, and POL genes |
AU2002320314A1 (en) * | 2001-07-05 | 2003-01-21 | Chiron, Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
CA2776391C (en) * | 2001-10-01 | 2015-03-31 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Development of a preventive vaccine for filovirus infection in primates |
-
2004
- 2004-09-15 EP EP04809757A patent/EP1675613B1/en not_active Not-in-force
- 2004-09-15 ES ES04809757T patent/ES2388527T3/es active Active
- 2004-09-15 WO PCT/US2004/030284 patent/WO2005034992A2/en active Application Filing
- 2004-09-15 CN CN2004800333502A patent/CN1913919B/zh not_active Expired - Fee Related
- 2004-09-15 CA CA2539068A patent/CA2539068C/en not_active Expired - Fee Related
- 2004-09-15 AU AU2004279362A patent/AU2004279362B2/en not_active Ceased
-
2006
- 2006-03-15 US US11/376,484 patent/US20060275897A1/en not_active Abandoned
- 2006-04-07 ZA ZA200602858A patent/ZA200602858B/xx unknown
-
2007
- 2007-06-13 US US11/818,113 patent/US7666427B2/en not_active Expired - Fee Related
-
2010
- 2010-01-07 US US12/683,844 patent/US7947822B2/en not_active Expired - Fee Related
-
2011
- 2011-04-14 US US13/086,884 patent/US8323961B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US8323961B2 (en) | 2012-12-04 |
US7666427B2 (en) | 2010-02-23 |
EP1675613A2 (en) | 2006-07-05 |
CN1913919B (zh) | 2011-10-19 |
EP1675613B1 (en) | 2012-05-23 |
CN1913919A (zh) | 2007-02-14 |
US20100111998A1 (en) | 2010-05-06 |
US20110274721A1 (en) | 2011-11-10 |
AU2004279362B2 (en) | 2011-03-17 |
AU2004279362A1 (en) | 2005-04-21 |
CA2539068A1 (en) | 2005-04-21 |
WO2005034992A2 (en) | 2005-04-21 |
US20080286306A1 (en) | 2008-11-20 |
US7947822B2 (en) | 2011-05-24 |
ES2388527T3 (es) | 2012-10-16 |
CA2539068C (en) | 2013-07-23 |
US20060275897A1 (en) | 2006-12-07 |
WO2005034992A3 (en) | 2005-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200602858B (en) | HIV vaccines based on Env of multiple clades of HIF | |
AU2003248872A8 (en) | Hiv integrase inhibitors | |
EP1756069A4 (en) | HIV INTEGRASE INHIBITORS | |
MXPA03003263A (es) | Aza y poliaza naftalenil carboxamidas utiles como inhibidores de la integrasa del virus de inmunodeficiencia humana. | |
IL222761A0 (en) | Viral polymerase inhibitors | |
IL179161A0 (en) | Hiv integrase inhibitors: cyclic pyrimidinone compounds | |
TWI347184B (en) | Methods of treating hiv infection | |
EP1603590A4 (en) | INFLUENZA VIRUS VACCINE | |
EP1572963A4 (en) | SYNTHETIC VACCINES CARBOHYDRATE BASE AGAINST HIV | |
NO20041157L (no) | HIV-GAG kodonoptimaliserte DNA-vaksiner | |
WO2008118849A3 (en) | Hiv-1 protease inhibitors | |
AU2003301850A8 (en) | Hiv vaccine | |
AU2002250078A1 (en) | Quantitative epstein barr virus pcr rapid assay | |
AU2003282498A8 (en) | Hiv vaccine formulations | |
IL189939A0 (en) | Inhibitors of the hiv integrase enzyme | |
WO2008063586A3 (en) | Multicomponent vaccine | |
AP2005003344A0 (en) | A group of nucleic acid fragments for prevention of HIV infection or AIDS and the usage thereof | |
EP1578461A4 (en) | VACCINES AGAINST HIV TAT PROTEIN FOR GENERATING NEUTRALIZING ANTIBODIES | |
WO2006052820A3 (en) | Human immunodeficiency virus vaccine | |
AU2003253255A1 (en) | An immunodeficiency virus (hiv) dna vaccine and to the process of preparation thereof | |
AU2002314274A1 (en) | Vaccination against the feline immunodeficiency virus | |
NO20012126D0 (no) | HIV-vaksine | |
AP2006003576A0 (en) | Entry inhibitors of the HIV virus. | |
AU2002355653A1 (en) | Vaccine comprising gp120 and nef and/or tat for the immunisation against hiv | |
AU2004900285A0 (en) | Detection of immunodeficiency viruses |